Introduction:The novel corona virus (SARS-CoV-19) is mainly accountable for the disease outbreak infection, which began in Wuhan, China, in 2019. Numerous modest research has been carried so far to ascertain the risks of smoking on the magnitude, consequence, and morbidity of patients with COVID-19, but the findings have been incomplete.Aims: This study assesses the effects of current smokers on the magnitude and consequence in patients with COVID-19 infectious disease in Mosul, Iraq.Materials and Methods: A total of 160 patients (80 active smokers and 80 non-smokers) who were confirmed with COVID-19 infection using polymerase chain reaction (PCR) test were enrolled in this study. A detailed history was obtained from of the subjects, as well as a thorough clinical evaluation and laboratory tests. The intensity of illness, biomarkers, D-dimer, liver enzymes (LFT), oxygen consumption, hospitalization, and outcome were all documented and analyzed between a two groups. Results and conclusion:The symptoms of COVID-19, measured laboratory markers were significantly higher in the sample of smokers compared to non-smokers. There has been no significant difference in the use of oxygen, hospitalization, ICU admission, death, or post-recovery problems. Serious clinical COVID-19 infection was much more prevalent in current smokers, and inflammatory markers such as D-dimer and LFT appeared greater in non -smokers than in smokers. There was no statistically significant difference in O2 usage, hospitalization, ICU admittance, death, or persistent morbidity.

BACKGROUND: Fibromyalgia is a common chronic condition characterized by widespread musculoskeletal pain together with mood and cognitive dysfunction. Data on the frequency of fibromyalgia in ischemic heart disease (IHD) are scarce. AIM: This study aimed to assess the frequency of fibromyalgia in IHD patients and to evaluate the characteristics of IHD patients with comorbid fibromyalgia. METHODS: The study was conducted in the coronary care unit, Department of Medicine in Ibn Sina Teaching Hospital in Mosul city, between March and November 2020. One hundred patients with IHD and 100 healthy controls were studied. The diagnosis of fibromyalgia was according to the 2011 modification of the 2010 American College of Rheumatology preliminary diagnostic criteria for fibromyalgia. Socio-demographic features and IHD characteristics of patients were recorded. RESULTS: The frequency of fibromyalgia was significantly higher among patients with IHD (29%) as compared to controls (7%). The mean age and proportion of women were significantly higher in IHD patients with fibromyalgia than those without fibromyalgia. It was also more common in patients with the present MI (p = 0.032) and in patients who had previous coronary angiography (p = 0.008). Patients with comorbid fibromyalgia had lower left ventricular ejection fraction (LVEF) (p = 0.0003) and higher scores on beck depression inventory (p = 0.0025). However, on multivariate logistic regression analysis, only two variables remained significant, (1) among IHD patients, fibromyalgia was more frequent in women (odds ratio [OR] = 3.839, p = 0.022) and (2) in patients having lower LVEF (OR = 0.917, p = 0.008). CONCLUSION: There is a high frequency of fibromyalgia in patients with IHD. Those IHD patients with comorbid fibromyalgia are more likely to be older, women, and with poor LVEF.

Background: The novel coronavirus ( SARS CoV 19) is responsible for the pandemic infection after starting in 2019 in Wuhan city /China, several small studies were done since then to determine the effects of smoking on the severity, outcome & mortality of patients with COVID-19 but the results were inconclusive, this study aims to assess the impact of active smoking on severity and outcome in patients with COVID-19 infection in Mosul city/Iraq. Methods: A prospective cohort study was conducted on 160 patients ( 80 patients were active smokers & 80 non-smoker patients) who have been diagnosed with COVID-19 infection by using real-time PCR, the study was done at Ibn-Sina teaching hospital in Mosul city/Iraq from May 2020 until December 2020. A detailed history was taken from the patients, full clinical examination & blood tests were done. The following parameters were recorded & compared between the 2 groups: severity of symptoms, inflammatory markers, D dimer, liver function test (LFT), oxygen use, hospitalization & outcome. Results: the symptoms of COVID-19 were more severe in the non smokers group (34.4%) compared to the smokers (25%) & it was statistically significant (p-value = 0.016), the inflammatory markers were also higher in the non-smokers (31.9%) compared to the smokers (20.0%) ( p-value = 0.011) , D dimer & LFT were also higher in the non-smoker group ( p-value = 0.01 & 0.008 respectively). There was no statistical difference regarding oxygen use, hospitalization, ICU admission, mortality, or post-recovery complications. Conclusion: severe symptomatic COVID-19 infection was more common in the non-smoker group, the inflammatory markers, D-dimer & LFT were higher in the non-smokers compared to the smokers. No statistical difference was found regarding O2 use, hospitalization, ICU admission, mortality & residual complications.